Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on June 4, 2025

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma Paris, France, June 4th, 2025. Oncovita, a biotechnology company developing innovative virus-based immunotherapies for …

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Southlake, TX, June 04, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focused on advancing the capabilities of ECGs/EKGs for the …

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
New 8-count bottles now available through major retail pharmacies ARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June 04, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals …

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement in OS and Progression Free Survival (“PFS”) Clinical …

Centurion Service Group to auction all assets following the closure of Crozer-Chester Medical Center in Upland, PA; Taylor Hospital in Ridley Park, PA; and Springfield Hospital in Springfield, PA
Franklin Park, Illinois, June 04, 2025 (GLOBE NEWSWIRE) -- Centurion Service Group, an industry-leading medical equipment life-cycle company, has been selected to auction all medical and non-medical assets of Crozer-Chester Medical Center in Upland, PA; …

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of …

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it …

Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glucose measurement technology RUTHERFORD, N.J., June 04, …

Synergy CHC Announces New $20 Million Long-Term Credit Facility
WESTBROOK, Maine, June 04, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it has entered into a $20 million term loan credit agreement, …

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial …

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market Evaluation of AZD5658 expands Conduit’s …

BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor
Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig”), which acquired Streamex Exchange Corporation as its wholly owned subsidiary (“Streamex”) in May 2025, is pleased to announce the …

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by …

FOXO TECHNOLOGIES INC. COMPLETES EQUITY FUNDING AGREEMENT
WEST PALM BEACH, FLORIDA, June 04, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that it has executed an agreement to issue 1,650 of its Series A Cumulative Convertible Redeemable Preferred …

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer …

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors Previous clinical proof-of concept data2 for targeting HER-2 …

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as …

Elicio Therapeutics Secures $10 Million in Financing
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage …

BeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health Treatments
LONG BEACH, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial™, recently achieved a major milestone with 35,000 Hydrafacial devices installed worldwide, reinforcing its market leadership …

Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
Collaboration will leverage Rosy Wellness’ extensive reach and community of over 250,000 women Rosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals Daré expects to start recording revenue in the 4th quarter this year …